Abstract
Although angiotensin II type 1 receptor blocker (ARB) therapy reduces proteinuria and retards the progression of renal injury in patients with glomerulonephritis, whether these drugs actually ameliorate pathological damages in human glomerulonephritis has not been determined. Fifteen patients with biopsy-proven mild-to-moderate mesangial proliferative glomerulonephritis (10 with immunoglobulin A [IgA] nephropathy and 5 with non-IgA mesangial proliferative glomerulonephritis) received ARB monotherapy. In these patients, repeated renal biopsy was performed after a mean of 28.1 months, and pathological changes (including the mesangial matrix expansion ratio and interstitial fibrosis expansion ratio) were quantitatively examined using an image analyzer. Clinical markers were also evaluated, including the serum creatinine, serum IgA, creatinine clearance (Ccr), 24-h urinary protein excretion, urinary N-acetyl-β-D-glucosaminidase (NAG), and blood pressure. ARB therapy significantly reduced urinary protein excretion (0.68±0.63 to 0.20±0.32 g/day, p=0.016) and the blood pressure (systolic: 133.3±18.2 to 123.4±10.5 mmHg, p=0.041; diastolic: 79.4±11.9 to 72.0±8.2 mmHg, p=0.038). Although the global glomerular sclerosis ratio was unchanged (6.3±8.5% to 10.7±16.1%, p=0.33), the mesangial matrix expansion ratio (33.1±10.8% to 22.7±7.8%, p=0.001) and the interstitial fibrosis ratio (19.9±5.8% to 13.8±4.4%, p=0.034) were significantly reduced by ARB treatment. The levels of pathological improvement were similar between patients with IgA nephropathy and those with non-IgA mesangial proliferative glomerulonephritis. The results of the present study strongly suggest that ARB monotherapy can significantly reverse pathological changes, including mesangial matrix expansion and interstitial fibrosis, in human glomerulonephritis.
Similar content being viewed by others
Article PDF
References
Lafayette RA, Mayer G, Park SK, Meyer TW : Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J Clin Invest 1992; 90: 766–771.
Mackenzie HS, Troy JL, Rennke HG, Brenner BM : TCV 116 prevents progressive renal injury in rats with extensive renal mass ablation. J Hypertens 1994; 12: S11–S16.
Kakinuma Y, Kawamura T, Bills T, et al: Blood pressure–independent effect of angiotensin inhibition on vascular lesions of chronic renal failure. Kidney Int 1992; 42: 46–55.
Pollok DM, Divish BJ, Polakowski JS, Opgenorth TJ : Angiotensin II receptor blockade improves renal function in rats with reduced mass. J Pharmacol Exp Ther 1993; 267: 657–663.
Brooks DP, Contino LC, Short BG, et al: A novel angiotensin II receptor antagonist and renoprotective agent. J Pharmacol Ther 1995; 274: 1222–1227.
Okada H, Suzuki H, Kanno Y, et al: Renal responces to angiotensin receptor antagonist and angiotensin converting enzyme inhibitor in partially nephrectomized spontaneously hypertensive rats. J Cardiovasc Pharmacol 1995; 26: 564–569.
Wu LL, Cox A, Roe CJ, et al: Transforming growth factor beta 1 and renal injury following subtotal nephrectomy in the rat: role of the renin-angiotensin system. Kidney Int 1997; 51: 1553–1567.
Ots M, Mackenzie HS, Troy JL, Brenner BM : Effects of combination therapy with enalapril and losartan on the rate of progression of renal injury in rats with 5/6 renal mass ablation. J Am Soc Nephrol 1998; 9: 224–230.
Nakamura T, Obata J, Kimura H, et al: Blocking angiotensin II ameliorates proteinuria and glomerular lesions in progressive mesangioproliferative glomerulonephritis. Kidney Int 1999; 55: 877–889.
Wolf G, Schneider A, Helmchen U, Stahl RAK : AT-receptor antagonists abolish glomerular MCP-1 expression in a model of mesangial proliferative glomerulonephritis. Exp Nephrol 1998; 6: 112–120.
Nangaku M, Miyata T, Sada T, et al: Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model. J Am Soc Nephrol 2003; 14: 1212–1222.
Perico N, Remuzzi A, Sangalli F, et al: The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin. J Am Soc Nephrol 1998; 9: 2308–2317.
Russo D, Pisani A, Balletta MM, et al: Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis 1999; 33: 851–856.
Russo D, Minutolo R, Pisani A, et al: Coadministration of losartan and enarapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis 2001; 38: 18–25.
Kuriyama S, Tomonari H, Tokudome G, et al: Antiproteinuric effects of combined antihypertensive therapies in patients with overt type 2 diabetic nephropathy. Hypertens Res 2002; 25: 849–855.
Lewis EJ, Hunsicker LG, Clarke WR, et al: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851–860.
Brenner BM, Cooper ME, de Zeeuw D, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–869.
Parving HH, Lehnert H, Bröchner-Mortensen J, et al: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870–878.
Usta M, Ersoy A, Dilek K, et al: Efficacy of losartan in patients with primary focal segmental glomerulosclerosis resistant to immunosuppressive treatment. J Intern Med 2003; 253: 329–334.
Yuan BH, Robinette JB, Conger JD : Effect of angiotensin II and norepinephrine on isolated rat afferent and efferent arterioles. Am J Physiol 1990; 258: F741–F750.
Takenaka T, Suzuki H, Fujiwara K, et al: Cellular mechanisms mediating rat renal microvascular constriction by angiotensin II. J Clin Invest 1997; 100: 2107–2114.
Wolf G, Mueller E, Stahl RAK, Ziyadeh FN : Angiotensin II–induced hypertrophy of cultured murine proximal tubular cells is mediated by endogenous transforming growth factor-β. J Clin Invest 1993; 92: 1366–1372.
Kagami S, Border WA, Miller DE, Noble NA : Angiotensin II stimulates extracellular matrix protein synthesis though induction of transforming growth factor-β expression in rat glomerular mesangial cells. J Clin Invest 1994; 93: 2431–2437.
Wolf G, Ziyadeh FN, Zahner G, Stahl RAK : Angiotensin II–stimulated expression of transforming growth factor beta in renal proximal tubular cells: attenuation after stable transfection with the c-mas oncogene. Kidney Int 1995; 48: 1818–1827.
Mezzano SA, Ruiz-Ortega M, Egido J : Angiotensin II and renal fibrosis. Hypertension 2001; 38: 635–638.
Border WA, Noble NA : Interactions of transforming growth factor-β and angiotensin II in renal fibrosis. Hypertension 1998; 31: 181–188.
Wolf G, Haberstroh U, Neilson EG : Angiotensin II stimulates the proliferation and biosynthesis of type 1 collagen in cultured murine mesangial cells. Am J Pathol 1992; 140: 95–107.
Gomez-Garre D, Ruiz-Ortega M, Ortego M, et al: Effects and interactions of endothelin-1 and angiotensin II on matrix protein expression and synthesis and mesangial cell growth. Hypertension 1996; 27: 885–892.
Kobayashi S, Moriya H, Nakabayashi I, et al: Angiotensin and IGF-1 may interact to regulate tubulointerstitial cell kinetics and phenotypic changes in hypertensive rats. Hypertens Res 2002; 25: 257–269.
Ruiz-Ortega M, Ruperez M, Lorenzo O, et al: Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney. Kidney Int 2002; 82: S12–S22.
Ruiz-Ortega M, Bustos C, Hernández-Presa MA, et al: Angiotensin II participates in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factor-κB activation and monocyte chemoattractant protein-1 synthesis. J Immunol 1998; 161: 430–439.
Lee FTH, Cao Z, Long DM, et al: Interactions between angiotensin II and NF-κB–dependent pathways in modulating macrophage infiltration in experimental diabetic nephropathy. J Am Soc Nephrol 2004; 15: 2139–2151.
Ma LJ, Nakamura S, Whitsitt JS, et al: Regression of sclerosis in aging by an angiotensin inhibition-induced decrease in PAI-1. Kidney Int 2000; 58: 2425–2436.
Remuzzi A, Gagliardini E, Donadoni C, et al: Effect of angiotensin II antagonism on the regression of kidney disease in the rat. Kidney Int 2002; 62: 885–894.
Aldigier JC, Kanjanbuch T, Ma LJ, et al: Regression of existing glomerulosclerosis by inhibition of aldosterone. J Am Soc Nephrol 2005; 16: 3306–3314.
Fiorreto P, Steffes MW, Sutherland DE, et al: Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998; 339: 69–75.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ohtake, T., Oka, M., Maesato, K. et al. Pathological Regression by Angiotensin II Type 1 Receptor Blockade in Patients with Mesangial Proliferative Glomerulonephritis. Hypertens Res 31, 387–394 (2008). https://doi.org/10.1291/hypres.31.387
Received:
Accepted:
Issue date:
DOI: https://doi.org/10.1291/hypres.31.387
Keywords
This article is cited by
-
Effect of treatment on urinary kidney injury molecule-1 in IgA nephropathy
BMC Nephrology (2013)
-
Thrombospondin-1 plays a profibrotic and pro-inflammatory role during ureteric obstruction
Kidney International (2012)
-
The role of renin angiotensin system inhibition in kidney repair
Fibrogenesis & Tissue Repair (2010)
-
Long-term study of mycophenolate mofetil treatment in IgA nephropathy
Kidney International (2010)
-
Emerging therapies for chronic kidney disease: what is their role?
Nature Reviews Nephrology (2009)
